ArticleBMC cancer2022

Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.

Ying Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.